EP2240158A2 - Stabilized injectable formulation of pregabalin - Google Patents

Stabilized injectable formulation of pregabalin

Info

Publication number
EP2240158A2
EP2240158A2 EP08869815A EP08869815A EP2240158A2 EP 2240158 A2 EP2240158 A2 EP 2240158A2 EP 08869815 A EP08869815 A EP 08869815A EP 08869815 A EP08869815 A EP 08869815A EP 2240158 A2 EP2240158 A2 EP 2240158A2
Authority
EP
European Patent Office
Prior art keywords
formulation
pregabalin
injectable
present
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08869815A
Other languages
German (de)
French (fr)
Inventor
Sehgal Ashish
Vallabhabhai Patel Bhavesh
Patel Aditya
Kumar Mandal Jayanta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intas Pharmaceuticals Ltd
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of EP2240158A2 publication Critical patent/EP2240158A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to stabilized injectable formulation of pregabalin and the process of preparing it.
  • This injectable formulation is administered intravenously to the patient requiring Pregabalin treatment.
  • Pregabalin was first disclosed in US patent no. 5,563,175 by Richard B. Silverman et al of the Northwestern University for the treatment of seizure disorder. Chemically Pregabalin is (S)-(+)-3-aminomethyl-5-methyl hexanoic acids.
  • Pregabalin is a structural analogue of, but functionally unrelated to, the naturally occurring transmitter GABA (gamma-aminobutyric acid).
  • GABA gamma-aminobutyric acid
  • Pregabalin acts by binding to the al ⁇ ha-2-delta subunit of voltage-gated calcium channels and is related to the endogenous inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is involved in the regulation of brain neuronal activity.
  • Pregabalin has been approved for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunctive treatment for partial onset seizures in adults.
  • Pregabalin is claimed to be used for treating pain which can be related to any of inflammatory, neuropathic, cancer, postoperative pain etc.
  • Pregabalin is thought to be useful for treating physiological conditions associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, and various psychiatric disorders, including mania and bipolar disorder.
  • Pregabalin is marketed by Pfizer in United States of America under the brand name of Lyrica in capsule dosage form in various strengths from 25mg to 300mg. Lyrica capsules are immediate release formulation and are administered to the patients two or three times daily.
  • PCT patent application no. WO2007052125 discloses matrix oral dosage form of pregabalin suitable for once a day administration whereas another PCT patent application no. WO2005063229 describes an oral liquid composition of Pregabalin.
  • injectable dosage form of pregabalin is still not reported. Injectable dosage form has its own advantage compared to other dosage forms. Injectable dosage forms provides quick onset of drug action compared to those administered orally. Also the therapeutic response of a drug is more readily controlled by injectable administration since the irregularities of intestinal absorption after oral administration of drag are circumvented.
  • Injectable dosage forms are normally administered by a professionally trained person, so it is expected that the dose is actually and accurately administered. Additionally when the patient is uncooperative or unconscious, it becomes difficult to administer the drug orally to the patient. In this case, an injectable dosage form is best suited for administration.
  • the inventors of the present invention have prepared an injectable dosage form of Pregabalin which is stable and well suited for administration to a patient.
  • the injectable formulation is administered intravenously, so the drug directly reaches into the bloodstream via a vein. This causes quick onset of drug action and the therapeutic effect is achieved much quicker.
  • the main object of the invention is to formulate an injectable dosage form of Pregabalin which is administered through intravenous, intramuscular, subcutaneous route or through infusion, preferably through intravenous route to a patient.
  • Additional object of the invention is to formulate iso-osmotic injectable dosage form of pregabalin.
  • One more object of the invention is to provide a process to formulate a stable injectable formulation of pregabalin using normal equipment for preparing injectable formulations.
  • the present invention provides a stable injectable formulation of pregabalin. Further, the present invention describes a process for the preparation of the said stable injectable formulation of pregabalin.
  • Formulating an injectable dosage form has many challenges compared to other dosage forms. As the drug is directly administered to blood circulation, it is essential that the formulation should be of high quality and should provide maximum safety to the patient. Choice of excipients and their quality is a critical factor in formulating an injectable dosage form.
  • the drug for present invention (Pregabalin) is susceptible to oxidation. Other challenges are with respect to the stability of the formulation. By maintaining a suitable pH condition Pregabalin injectable formulation remains stable. Considering these, the inventor of the present invention has formulated an injectable formulation of pregabalin which is stable and well suited for intravenous administration to a patient. It may also be diluted in commonly used intravenous fluids for infusion administration thereby allowing the drug to be administered with greater regularity in order to obtain a more precise and safer effect.
  • the injection prepared according to the present invention is a clear colourless solution. So any foreign particles, such as glass residues, fibers, undissolved substances and the like, inside the ampoule or vials is well controlled. This is particularly required while formulating an intravenous injection.
  • the formulation of the present invention apart from the active pharmaceutical ingredient comprises of pharmaceutically acceptable excipients like vehicle, tonicity adjusting agent, buffering agent, anti-oxidants, pH adjusting agent and other excipients suitable to be used for an intravenous injection.
  • Vehicles are inert and non-toxic substances having no therapeutic activity. These are administered to provide an effective dose of the active ingredient. They present to body tissues the form of the active ingredient for absorption.
  • Vehicles used in the present formulation can be selected from aqueous vehicle, water miscible vehicle and nonaqueous vehicle.
  • Aqueous vehicle can be water whereas water miscible vehicles are solvents miscible with water.
  • the water miscible vehicles can be ethyl alcohol, polyethylene glycol, propylene glycol and the likes.
  • Non-aqueous vehicles can be fixed oils.
  • the preferred vehicle used in the formulation of present invention is water for injection (WFI).
  • An intravenous injection is required to be isotonic with body fluids.
  • isotonic means that the formulation has essentially the same osmotic pressure as human blood.
  • tonicity adjusting agent or tonicity modifiers are used.
  • Tonicity modifiers suitable for this invention include salts and amino acids.
  • the preferred tonicity modifier used is sodium chloride. Desired tonicity of the formulation is between 200 to 400, more preferably the desired tonicity of the formulation is 300.
  • Stability of the formulation of present invention is pH dependent. During the manufacturing process, the pH of the formulation of present invention is essentially maintained at a range of 5.8 to 6.2, preferably at pH 6.0. This enhances the stability of the injectable formulation.
  • a pH adjusting agent is used which can be acid or base.
  • the base can be oxides, hydroxides, carbonates, bicarbonates and the likes.
  • the oxides can be metal oxides such as calcium oxide, magnesium oxide and the likes; hydroxides can be of alkali metals and alkaline earth metals such as sodium hydroxide, potassium hydroxide, calcium hydroxide and the likes and carbonates can be sodium carbonate, sodium bicarbonates, potassium bicarbonates and the likes.
  • the acid can be mineral acid and organic acids such as hydrochloric acid, nitric acid, phosphoric acid, acetic acid, citric acid, fumaric acid, malic acid tartaric acid and the likes.
  • the preferred base and acid used in the formulation of present invention for pH adjustment are sodium hydroxide and hydrochloric acid respectively.
  • a buffering agent is also used in the formulation of present invention to stabilize the formulation against chemical degradation that might occur due to pH drift.
  • the buffering agents used in the formulation of present invention can be citrates, acetates, phosphates other organic buffers and the likes.
  • the preferred buffering agent used in present case is citric acid monohydrate.
  • Pregabalin is susceptible to oxidation and to prevent this, an antioxidant is used in the formulation.
  • An antioxidant is a molecule capable of slowing or preventing the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals, which start chain reactions that can have adverse effect on the purity and stability of the formulation. Antioxidants terminate these chain reactions by removing free radical . intermediates, and inhibit other oxidation reactions by being oxidized themselves.
  • Sulfites like sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium formaldehyde sulfoxylate, thiourea, sequestering agents such as sodium salt of ethylenediaminetetraacetic acid (EDTA) and acids such as citric acid and the likes can be used as antioxidant.
  • EDTA ethylenediaminetetraacetic acid
  • the process for the preparation of injectable pregabalin formulation according to the present inventions comprises the steps of:
  • Nitrogen sparging helps in removing dissolved oxygen from the solution and hence minimizes oxidative degradation of oxidation susceptible drugs.
  • the injectable pregabalin formulation is stable at pH between 4.0 to 8.0, more preferably between pH 5.0 to 7.0.
  • the process of preparation of formulation of the present invention does not require any particular or sophisticated apparatus. It is sufficient to use normal equipments to prepare the pharmaceutical formulations of present invention for injectable use.
  • Process of preparation comprise of following steps:
  • the pH was adjusted in the range of 5.8 - 6.2 preferably at 6.0 with IN sodium hydroxide solution and / or hydrochloric acid solution.
  • Pregabalin was then added and dissolved with continuous nitrogen sparging. If required the pH was adjusted to 6.0 (in the range of range 5.8 - 6.2) with IN sodium hydroxide solution and / or hydrochloric acid.
  • PVDF polyvinylfluoridine
  • This formulation can be prepared by following the process mentioned in the earlier example.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an injectable pregabalin formulation which is stable in between pH 4.0 to 8.0. Further, the present invention relates to a process for manufacturing the said injectable pregabalin formulation. The injectable formulation of pregabalin according to the present invention is administered intravenously to the patients requiring pregabalin treatment.

Description

Field of the invention:
The present invention relates to stabilized injectable formulation of pregabalin and the process of preparing it. This injectable formulation is administered intravenously to the patient requiring Pregabalin treatment.
Background and Prior Art:
Pregabalin was first disclosed in US patent no. 5,563,175 by Richard B. Silverman et al of the Northwestern University for the treatment of seizure disorder. Chemically Pregabalin is (S)-(+)-3-aminomethyl-5-methyl hexanoic acids.
Pregabalin is a structural analogue of, but functionally unrelated to, the naturally occurring transmitter GABA (gamma-aminobutyric acid). Pregabalin acts by binding to the alρha-2-delta subunit of voltage-gated calcium channels and is related to the endogenous inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is involved in the regulation of brain neuronal activity.
In the United States, Pregabalin has been approved for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunctive treatment for partial onset seizures in adults.
In US patent no. 6,001,876 Pregabalin is claimed to be used for treating pain which can be related to any of inflammatory, neuropathic, cancer, postoperative pain etc.
Pregabalin is thought to be useful for treating physiological conditions associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, and various psychiatric disorders, including mania and bipolar disorder.
Pregabalin is marketed by Pfizer in United States of America under the brand name of Lyrica in capsule dosage form in various strengths from 25mg to 300mg. Lyrica capsules are immediate release formulation and are administered to the patients two or three times daily. PCT patent application no. WO2007052125 discloses matrix oral dosage form of pregabalin suitable for once a day administration whereas another PCT patent application no. WO2005063229 describes an oral liquid composition of Pregabalin.
Though solid oral and liquid oral dosage forms of pregabalin are known, injectable dosage form of pregabalin is still not reported. Injectable dosage form has its own advantage compared to other dosage forms. Injectable dosage forms provides quick onset of drug action compared to those administered orally. Also the therapeutic response of a drug is more readily controlled by injectable administration since the irregularities of intestinal absorption after oral administration of drag are circumvented.
Injectable dosage forms are normally administered by a professionally trained person, so it is expected that the dose is actually and accurately administered. Additionally when the patient is uncooperative or unconscious, it becomes difficult to administer the drug orally to the patient. In this case, an injectable dosage form is best suited for administration.
The inventors of the present invention have prepared an injectable dosage form of Pregabalin which is stable and well suited for administration to a patient. The injectable formulation is administered intravenously, so the drug directly reaches into the bloodstream via a vein. This causes quick onset of drug action and the therapeutic effect is achieved much quicker.
Object of the Invention:
The main object of the invention is to formulate an injectable dosage form of Pregabalin which is administered through intravenous, intramuscular, subcutaneous route or through infusion, preferably through intravenous route to a patient.
Additional object of the invention is to formulate iso-osmotic injectable dosage form of pregabalin. One more object of the invention is to provide a process to formulate a stable injectable formulation of pregabalin using normal equipment for preparing injectable formulations.
Summary of the Invention:
The present invention provides a stable injectable formulation of pregabalin. Further, the present invention describes a process for the preparation of the said stable injectable formulation of pregabalin.
Detail Description of the Invention:
Formulating an injectable dosage form has many challenges compared to other dosage forms. As the drug is directly administered to blood circulation, it is essential that the formulation should be of high quality and should provide maximum safety to the patient. Choice of excipients and their quality is a critical factor in formulating an injectable dosage form.
The drug for present invention (Pregabalin) is susceptible to oxidation. Other challenges are with respect to the stability of the formulation. By maintaining a suitable pH condition Pregabalin injectable formulation remains stable. Considering these, the inventor of the present invention has formulated an injectable formulation of pregabalin which is stable and well suited for intravenous administration to a patient. It may also be diluted in commonly used intravenous fluids for infusion administration thereby allowing the drug to be administered with greater regularity in order to obtain a more precise and safer effect.
The injection prepared according to the present invention is a clear colourless solution. So any foreign particles, such as glass residues, fibers, undissolved substances and the like, inside the ampoule or vials is well controlled. This is particularly required while formulating an intravenous injection.
The formulation of the present invention apart from the active pharmaceutical ingredient (Pregabalin) comprises of pharmaceutically acceptable excipients like vehicle, tonicity adjusting agent, buffering agent, anti-oxidants, pH adjusting agent and other excipients suitable to be used for an intravenous injection.
Vehicles are inert and non-toxic substances having no therapeutic activity. These are administered to provide an effective dose of the active ingredient. They present to body tissues the form of the active ingredient for absorption. Vehicles used in the present formulation can be selected from aqueous vehicle, water miscible vehicle and nonaqueous vehicle. Aqueous vehicle can be water whereas water miscible vehicles are solvents miscible with water. The water miscible vehicles can be ethyl alcohol, polyethylene glycol, propylene glycol and the likes. Non-aqueous vehicles can be fixed oils. The preferred vehicle used in the formulation of present invention is water for injection (WFI).
An intravenous injection is required to be isotonic with body fluids. The term isotonic means that the formulation has essentially the same osmotic pressure as human blood. To make the formulation isotonic, tonicity adjusting agent or tonicity modifiers are used. Tonicity modifiers suitable for this invention include salts and amino acids. The preferred tonicity modifier used is sodium chloride. Desired tonicity of the formulation is between 200 to 400, more preferably the desired tonicity of the formulation is 300.
Stability of the formulation of present invention is pH dependent. During the manufacturing process, the pH of the formulation of present invention is essentially maintained at a range of 5.8 to 6.2, preferably at pH 6.0. This enhances the stability of the injectable formulation. For pH adjustment, a pH adjusting agent is used which can be acid or base. The base can be oxides, hydroxides, carbonates, bicarbonates and the likes. The oxides can be metal oxides such as calcium oxide, magnesium oxide and the likes; hydroxides can be of alkali metals and alkaline earth metals such as sodium hydroxide, potassium hydroxide, calcium hydroxide and the likes and carbonates can be sodium carbonate, sodium bicarbonates, potassium bicarbonates and the likes. The acid can be mineral acid and organic acids such as hydrochloric acid, nitric acid, phosphoric acid, acetic acid, citric acid, fumaric acid, malic acid tartaric acid and the likes. The preferred base and acid used in the formulation of present invention for pH adjustment are sodium hydroxide and hydrochloric acid respectively.
A buffering agent is also used in the formulation of present invention to stabilize the formulation against chemical degradation that might occur due to pH drift. The buffering agents used in the formulation of present invention can be citrates, acetates, phosphates other organic buffers and the likes. The preferred buffering agent used in present case is citric acid monohydrate.
Pregabalin is susceptible to oxidation and to prevent this, an antioxidant is used in the formulation. An antioxidant is a molecule capable of slowing or preventing the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals, which start chain reactions that can have adverse effect on the purity and stability of the formulation. Antioxidants terminate these chain reactions by removing free radical . intermediates, and inhibit other oxidation reactions by being oxidized themselves. Sulfites like sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium formaldehyde sulfoxylate, thiourea, sequestering agents such as sodium salt of ethylenediaminetetraacetic acid (EDTA) and acids such as citric acid and the likes can be used as antioxidant.
The process for the preparation of injectable pregabalin formulation according to the present inventions comprises the steps of:
Take water for injection (90% of batch size) in SS container and sparge with 0.2μ filtered nitrogen until the levels of dissolved oxygen comes to less than lppm. Add and dissolve sodium chloride and citric acid monohydrate with continuous nitrogen sparging. Adjust pH to 6.0 (range 5.8 - 6.2) with IN sodium hydroxide solution and / or hydrochloric acid solution. Add and dissolve pregabalin with continuous nitrogen sparging. Adjust pH to 6.0 (range 5.8 — 6.2) if required with ITSf sodium hydroxide solution and / or hydrochloric acid. Make up the volume to required batch size with nitrogen sparged water for injection. Continue nitrogen sparging for 30 minutes after batch manufacturing. Filter the bulk solution through 0.2μ polyvinylfluoridine filter by using nitrogen gas. Fill the filtered bulk solution (3.1 ml (range 3.2ml ± 0.1ml)) into 5ml clear glass USP type I ampoules pre and post nitrogen gas flushing.
Nitrogen sparging helps in removing dissolved oxygen from the solution and hence minimizes oxidative degradation of oxidation susceptible drugs.
According to the present invention, the injectable pregabalin formulation is stable at pH between 4.0 to 8.0, more preferably between pH 5.0 to 7.0.
Throughout this specification it is to be understood that the words "comprise" and "include" and variations such as "comprises", "comprising", "includes", "including" are to be interpreted inclusively, unless the context requires otherwise. That is, the use of these words may imply the inclusion of an element or elements not specifically recited.
Example:
The present invention has been described by way of example only, and it is to be recognized that modifications thereto falling within the scope and spirit of the description, and which would be obvious to a person skilled in the art based upon the disclosure herein, are also considered to be included within the scope of this invention. The formulation according to present invention can be illustrated by but not limited to following example(s).
Following example mentions about the formulation with excipients and its amount range which can be used in the formulation:
Process of Preparation:
The process of preparation of formulation of the present invention does not require any particular or sophisticated apparatus. It is sufficient to use normal equipments to prepare the pharmaceutical formulations of present invention for injectable use.
Process of preparation comprise of following steps:
1. Water for injection (90% of batch size) was taken in stainless steel container. It was sparged with 0.2 micron filtered nitrogen until dissolved oxygen level comes to less than lppm.
2. After this, sodium chloride and citric acid monohydrate was added and dissolved with continuous nitrogen sparging.
3. The pH was adjusted in the range of 5.8 - 6.2 preferably at 6.0 with IN sodium hydroxide solution and / or hydrochloric acid solution.
4. Pregabalin was then added and dissolved with continuous nitrogen sparging. If required the pH was adjusted to 6.0 (in the range of range 5.8 - 6.2) with IN sodium hydroxide solution and / or hydrochloric acid.
5. The volume was made-up to require batch size with nitrogen sparged water for injection. Nitrogen sparging was continued for 30 minutes after batch manufacturing.
6. The bulk solution was then filtered through 0.2 micron polyvinylfluoridine (PVDF) filter by using nitrogen gas. 7. The filtered bulk solution was finally filled in manner as described below:
3.1 mL (Range 3.2mL ± O.lmL) into 5mL clear glass USP Type I ampoules pre and post nitrogen gas flushing.
Formulation:
The following example mentions about stable injectable pregabalin formulation with stability data.
* _ Target pH range is in between 5.8 to 6.2
This formulation can be prepared by following the process mentioned in the earlier example.
Below mentioned table mentions about the data for stability studies conducted for the exemplified formulation. Stability study data:
CCS - clear colourless solution

Claims

We claim:
1. An injectable formulation of pregabalin.
2. The formulation as claimed in claim 1, wherein the pH of the formulation is between 4.0 to 8.0, more preferable pH of the formulation is between 5.0 to 7.0.
3. The formulation as claimed in claim 1, wherein the vehicle of formulation can be aqueous, water miscible or non-aqueous.
4. The formulation as claimed in claim 1, further comprises of atleast one of pharmaceutical excipients; either tonicity adjusting agent, buffering agent, anti-oxidants, pH adjusting agent or mixtures thereof.
5. The formulation as claimed in claim 4, wherein the anti-oxidants can be sulfites, acids or sequestering agents.
6. The formulation as claimed in claim 1, wherein the amount of pregabalin is in the range of 5 to 35 mg/ml of the formulation.
7. A process for preparation of an injectable formulation of pregabalin stable at a pH in between 4.0 - 8.0 comprises the steps of: a) Dissolving tonicity adjusting agent and buffering agent in formulation solvent, b) Adjusting the pH in between 5.8 to 6.2 using pH adjusting agent, c) Adding and dissolving pregabalin, d) Adjusting the pH in between 5.8 to 6.2, if required, e) Making up the required volume.
8. An injectable formulation of pregabalin stable at a pH between 4.0 to 8.0 comprises of:
Fregabalin — 5 - 35mg
Tonicity agent - q.s to adjust to desired tonicity
Buffering agent - 0 - lOmg pH adjusting agent - q.s to pH
Formulation vehicle — q.s ImI
EP08869815A 2007-12-28 2008-12-26 Stabilized injectable formulation of pregabalin Withdrawn EP2240158A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2596MU2007 2007-12-28
PCT/IN2008/000869 WO2009087682A2 (en) 2007-12-28 2008-12-26 Stabilized injectable formulation of pregabalin

Publications (1)

Publication Number Publication Date
EP2240158A2 true EP2240158A2 (en) 2010-10-20

Family

ID=40801860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08869815A Withdrawn EP2240158A2 (en) 2007-12-28 2008-12-26 Stabilized injectable formulation of pregabalin

Country Status (2)

Country Link
EP (1) EP2240158A2 (en)
WO (1) WO2009087682A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498611B (en) * 2019-01-15 2020-09-01 张惊宇 Medicine for treating diabetic peripheral neuralgia and application thereof
US20220175707A1 (en) 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
EP4138818B1 (en) * 2020-08-28 2024-08-21 Cybin UK Ltd Injectable formulation
CN112353767A (en) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 Diltiazem hydrochloride and pregabalin composition, and preparation method and application thereof
CN113069411B (en) * 2021-04-02 2022-08-09 石家庄四药有限公司 Pentoxifylline injection and preparation method thereof
WO2022256545A1 (en) * 2021-06-04 2022-12-08 Nevakar Injectables Inc. Injectable pregabalin formulations
GB2624861A (en) 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
JP2002541198A (en) * 1999-04-08 2002-12-03 ワーナー−ランバート・カンパニー Treatment of incontinence
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
EP1992609A1 (en) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009087682A3 *

Also Published As

Publication number Publication date
WO2009087682A3 (en) 2009-09-11
WO2009087682A2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2009087682A2 (en) Stabilized injectable formulation of pregabalin
JP2572768B2 (en) A therapeutic agent for Parkinson's disease containing levodopa methyl ester as an active ingredient
US10201519B2 (en) Stabilized pediatric suspension of carisbamate
KR100730502B1 (en) Pharmaceutical tramadol salts and forms of administration containing them
US20160271252A1 (en) Stable cannabinoid formulations
KR20090057349A (en) Long term 24 hour intestinal administration of levodopa/carbidopa
JP2004534764A (en) Liquid pharmaceutical composition
JP2012515154A (en) Formulation for oral mucosal administration of analgesic molecule and / or antispasmodic molecule
US20130109729A1 (en) Pharmaceutical composition
WO2020039262A1 (en) Pharmaceuticals solution for oral dosage
US20050171203A1 (en) Pregabalin composition
WO2015144825A1 (en) Oral liquid pharmaceutical solution of gabapentin
US20080138383A1 (en) Compositions and methods for treating seizures
JP2007508313A (en) Methylphenidate solution and related administration and manufacturing methods
WO2004098614A1 (en) Freeze-dried preparation containing methylcobalamin and process for producing the same
US20150272872A1 (en) Oromucosal Apomorphine Compositions
CA2446160A1 (en) Combination comprising a p-gp inhibitor and an anti-epileptic drug
MX2013012827A (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof.
JP2012512851A (en) Formulation for buccal transmucosal administration of setron
WO2020053658A2 (en) Non-aqueous chemotherapeutic solutions for oral dosage
JP6935930B2 (en) Prophylactic or therapeutic agent for pulmonary hypertension containing crude drug ingredients
CN117279634A (en) Pharmaceutical composition comprising compound SMTP-7
KR20170099911A (en) Injectable formulations of paracetamol
RU2071772C1 (en) Medicinal agent for multiple sclerosis treatment
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150701